TOKYO, May 15 (Pulse News Wire) – Astellas Pharma Inc. (4503.T) announced today that its board of directors approved the continuation of its performance-based equity compensation program for fiscal year 2026.
The plan targets executive officers and will run through March 2029. Under the program, eligible executives will receive shares based on the company's Total Shareholder Return (TSR) compared to the Nikkei 225 index growth rate and a peer group of global pharmaceutical companies. The performance multiplier range is set between 0% and 200%.
Shares will be delivered around June 2029, subject to meeting certain conditions such as continued employment until June 1, 2029. The trust fund for the program will be funded with approximately ¥1.116 billion, with up to ¥1.640 billion worth of shares potentially distributed during the three-year period. Any remaining shares at the end of the trust term will either be used for future incentive plans or transferred back to the company for cancellation.
Additionally, the company retains the right to clawback payments made to executives if significant accounting errors or misconduct occur during the plan period.
🟡 Confidence: Standard AI-translated content.